Skip to main content
BHC logo

BHC · Bausch Health Companies Inc.

Track BHC — free
$8.56 -0.17 (-1.95%) At close · Nov 19
Market Cap
$3.20B
Shares
374.27M
Volume · Nov 19 3.27M Avg daily vol (3M) 3.15M

Price & Indicators

 

Key stats

Close
$8.56
Open
$8.71
Day range
$8.55–8.84
52-week closing range
$4.43–8.91
Average volume, 30 days
4.1M
Short interest
7.4M · 2.0% of shares · 1.2 days
Short volume, last session
29%
Last earnings
Oct 28, 2026
Latest filing
10-Q · Oct 29
Price history
Jan 2020 to Nov 2026

Up next

Feb 17, 2027 Est · unconfirmed · in 13 wks

Latest documents

2026
Oct 29
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Refinancing extended $6,870 million of maturities through 2032

Bausch Health Companies Inc. says refinancing extended approximately $6,870 million of debt maturities from 2025 through 2028 to 2030 through 2032 while it continues evaluating separation of approximately 87%-owned Bausch + Lomb.

Revenue $2.94B ▲ 9.7% Net income $436M ▲ 143.6% Diluted EPS $1.15 ▲ 139.6%
Read from the MD&A section
3 source passages
The April 2025 Refinancing Transactions reduced our short-term cash requirements for debt service by extending approximately $6,870 million in aggregate debt maturities from the years 2025 through 2028 to the years 2030 through 2032. Bausch Health currently indirectly holds 310,449,643 common shares of Bausch + Lomb, which represents approximately 87% of B+L’s outstanding common shares as of October 21, 2026. The terms “we,” “us,” “our,” “the Company,” “Bausch Health,” and similar terms refer to Bausch Health Companies Inc. and its subsidiaries, taken together. Open the document at this passage
Oct 28
Earnings call
Raises full-year guidance again as net debt falls $521 million

Bausch Health raised its full-year 2026 guidance for the second time this year, with revenue now expected between $5,525,000,000 and $5,625,000,000 and adjusted EBITDA between $3,225,000,000 and $3,275,000,000. Revenues reached $2,941,000,000, a 10% increase on reported basis. The company also reduced its net debt by $521 million during the quarter.

6 source passages
In closing, 2026 is shaping up to be another strong year for Bausch Health. We are raising our full year guidance for the second time this year and look forward to closing out the year operationally on a strong note. Revenue is expected to be between $5,525,000,000 and $5,625,000,000. Adjusted EBITDA is now expected to be between $3,225,000,000 and $3,275,000,000. Revenues were $2,941,000,000, a 10% increase on reported basis and 8% on an organic basis compared to the same period a year ago. we were able to reduce our net debt by $521 million during the quarter. Open the document at this passage
Oct 28
Current report 8-K
Third-quarter revenue rises 10% to $2.94 billion; guidance raised

Bausch Health reported third-quarter 2026 revenue of $2.94 billion, up 10% from $2.68 billion a year earlier, and GAAP net income attributable to Bausch Health of $436 million. Adjusted earnings per diluted share rose to $1.77 from $1.16, and full-year 2026 revenue and Adjusted EBITDA guidance was raised. The Board authorized a $50 million share repurchase program.

Financial results Read from the first part of this long document
5 source passages
Total consolidated reported revenues were $2.94 billion for the third quarter of 2026, compared with $2.68 billion in the third quarter of 2025, an increase of $260 million, or 10%. GAAP Net Income Attributable to Bausch Health of $436 million and GAAP Net Income of $446 million Adjusted Earnings per Diluted Share1 of $1.77 compared to $1.16 in the prior year period Raising full year 2026 Revenue, Adjusted EBITDA1, and Adjusted Cash Flows from Operations1 guidance The Company also announced that its Board of Directors has authorized a $50 million share repurchase program Open the document at this passage
Jul 30
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $2.85B ▲ 12.7% Net income $258M ▲ 74.3% Diluted EPS $0.68 ▲ 70.0%
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$11.11B
Trailing 12 months
Net income (TTM)
−$841.00M
Trailing 12 months
Revenue growth YoY
+9.7%
Year over year
Operating margin
11.2%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
58.2%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$18.15B
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+1.4%
Year over year · more shares
Price change (1Y)
+41.5%
Trailing year
Short interest
2.0%
Latest settlement · 1.2 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Oct 28, 2026
Q3 FY26

TL;DR. Third-quarter revenue, adjusted EBITDA and operating cash flow grew strongly, management raised full-year guidance for all three metrics, and net debt declined by $521 million during the quarter. Offsetting these gains, Xifaxan pricing and inventory headwinds are expected to pressure Q4 and 2027, Solta organic revenue declined 4%, and tariffs remain an uncertain risk.

Bullish
  • + Third-quarter consolidated revenue rose 10% to $2,941,000,000, adjusted EBITDA rose 32% to $1,305,000,000, and adjusted cash flow from operations rose 54% to $782 million.
  • + Management raised full-year 2026 guidance for revenue, adjusted EBITDA, and adjusted cash flow from operations for the second consecutive quarter.
  • + The updated Bausch Health guidance excluding Bausch + Lomb calls for revenue of $5.525 billion to $5.625 billion, adjusted EBITDA of $3.225 billion to $3.275 billion, and adjusted cash flow from operations of $1.600 billion to $1.675 billion.
  • + Cash generation reduced net debt by $521 million during the quarter and by more than a billion dollars since the beginning of the year, while the company ended with $2 billion of cash on hand.
  • + Salix revenue increased 16% to $831 million, led by 16% Xifaxan growth from favorable pricing and solid demand.
  • + International revenue grew 4% organically, with EMEA delivering a 15th consecutive quarter of organic growth and Canada returning to growth.
Bearish
  • − The anticipated Xifaxan Medicare price change is expected to reduce Q4 revenue growth by 800 basis points and adjusted EBITDA growth by 1,400 basis points.
  • − Xifaxan inventory normalization could further reduce Q4 revenue growth by at least 300 basis points and adjusted EBITDA growth by 500 basis points.
  • − The net impact of Xifaxan pricing and rebate changes is expected to reduce 2027 revenue by approximately $400 million to $500 million year over year.
  • − Solta Medical organic revenue declined 4% in the third quarter despite reported growth of 18%.
  • − The company incurred a $1,426 million goodwill impairment during the first nine months and reported a nine-month net loss attributable to Bausch Health of $729 million.
  • − Tariff developments create uncertainty, and the company said there can be no assurance that the impacts will not be adverse.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Buy Momentum Very Strong Sentiment Bullish Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 28.4 · fear Equity put/call 0.72
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +46%
above
Price vs 50-day avg +27%
above
RSI (14) 66
neutral
MACD trend Negative
52-week position 92%
near high
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +32%
trailing
6-month return +61%
trailing
YTD return +23%
this year
Relative strength +67%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $7 › 200d $6 — 50d above 200d
Institutional flow Accumulating
+5% holders QoQ · +38 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
1.98% of shares out · ▼ -10.1% MoM · 1.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
234 holders — mid 3-yr range
Squeeze score 50
elevated · 0–100
Fundamentals
Strong
Revenue growth −10%
Y/Y
EPS growth +423%
Y/Y
Free cash flow $1.0B
Buyback $50.0M
authorized
Balance sheet $19.5B
net debt
Quant / Vol
risk profile
Very High
Volatility 62%
annualized · 1-yr
Max drawdown −44%
past year
ATR 4.1%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 4 of last 4
Latest guidance · from the 8-K filed Oct 28, 2026
Revenue growth vs. Prior Year (BHC excl. B+L) · full year 2026 Raised 7% – 9%
Jul 29, 2026 4% – 6% changed to Oct 28, 2026 7% – 9%
Adj. EBITDA growth vs. Prior Year (BHC excl. B+L) · full year 2026 Non-GAAP 12% – 14%
Previous outlook earlier release · from the 8-K filed Jul 29, 2026

Still-open targets the latest release did not restate under the same label.

Adjusted EBITDA (BHC) · full-year 2026 $4.05B – $4.18B
Adjusted EBITDA (BHC excl. B+L) · full-year 2026 $3.03B – $3.1B
Adjusted EBITDA (B+L) · full-year 2026 $1.03B – $1.08B
Guided vs delivered · last 4 settled
Full year revenue Full year 2023
guided $8.35B – $8.55B
$8.76B Beat +3.6%
Full year revenue full year 2022
guided $8B – $8.17B
$8.12B In line
Full-year revenue range full year of 2021
guided $8.4B – $8.6B
$8.43B In line
Revenue full-year 2020
guided $7.8B – $8B
$8.03B Beat +1.6%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy
1 · 3 · 3
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+46% Bullish
Price vs 50-day avg
+27% Bullish
RSI (14)
66 Neutral
MACD trend
Negative Bearish
52-week position
92% Bullish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $7 › 200d $6 — 50d above 200d
Institutional flow Accumulating
+5% holders QoQ · +38 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
1.98% of shares out · ▼ -10.1% MoM · 1.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
234 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $4 Now $9 · 92% Range high $9
vs 200-day avg +46% vs 50-day avg +27%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Organic Revenue (Non-GAAP) - Bausch + Lomb non-GAAP $1.38B the three months ended June 30, 2026 filing —
Organic Revenue (Non-GAAP) - Diversified non-GAAP $219M the three months ended June 30, 2026 filing —
Organic Revenue (Non-GAAP) - International non-GAAP $293M the three months ended June 30, 2026 filing —
Organic Revenue (Non-GAAP) - Salix non-GAAP $758M the three months ended June 30, 2026 filing —
Organic Revenue (Non-GAAP) - Solta Medical non-GAAP $143M the three months ended June 30, 2026 filing —
Adjusted Cash Flows from Operations non-GAAP $471M the second quarter of 2026 —
Adjusted cash flows from operations (non-GAAP) non-GAAP $1.01B Six Months Ended June 30, 2026 —
Adjusted EBITDA (non-GAAP) non-GAAP $1.97B Six Months Ended June 30, 2026 —
Adjusted EBITDA attributable to Bausch Health Companies Inc. (non-GAAP) non-GAAP $1.91B Six Months Ended June 30, 2026 —
Consolidated adjusted earnings per share attributable to Bausch Health (non-GAAP) non-GAAP $1.26 the second quarter of 2026 —
Consolidated adjusted net income attributable to Bausch Health (non-GAAP) non-GAAP $476M the second quarter of 2026 —
GAAP → non-GAAP reconciliation
GAAP Net income (loss) attributable to Bausch Health Companies Inc. 258M
+225M Amortization of intangible assets
+0M Goodwill impairments
+9M Asset impairments
+14M Restructuring, integration and transformation costs
+6M Acquisition-related costs and adjustments (excluding amortization of intangible assets)
+0M (Gain) loss on extinguishment of debt and write down of financing fees
+1M Separation costs and separation-related costs
+0M Gain on sale of assets, net
+6M Litigation and other matters, net of insurance recoveries and restitutions
+6M Other
-35M Tax effect of non-GAAP adjustments
-14M Noncontrolling interest portion of the non-GAAP adjustments
= Adjusted net income attributable to Bausch Health Companies Inc. (non-GAAP) 476M
Organic Revenue (Non-GAAP) non-GAAP $5.21B Six Months Ended June 30, 2026 —
Organic Revenue Growth (Salix segment) non-GAAP 21% the second quarter of 2026 —
Organic Revenue Growth (Total Bausch Health) non-GAAP 11% the second quarter of 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Drug Manufacturers - Specialty & Generic — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
BHC
Bausch Health Companies Inc.
this stock
$3.20B +23.2% -9.8% — 2.0%
TAK
Takeda Pharmaceutical Co Ltd
$68.40B +37.3% — — 0.1%
GALDY
Galderma Group AG
$50.89B +5.3% — — 0.0%
TEVA
Teva Pharmaceutical Industries Ltd
$44.97B +23.5% +4.3% 87.6 2.4%
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
$40.66B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
234
% held
59.7%
Net QoQ
-13.6M sh
Top holder
PAULSON & CO. INC.
Held Float
View
Held by Funds
Fund positions
76
View
Short & Settlement
Short Interest Falling
Shares short
7.4M
Days to cover
1.2d
Change
-833.6K sh
View
Short Volume
Short vol %
29%
As of
Nov 19, 2026
Short Total
View
Fails to Deliver
FTD shares
38.9K
Value
$346.2K
As of
Oct 30, 2026
View
Off-Exchange
Off-exchange %
40.6%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Congressional Trades Sell
Member
Susie Lee
Amount
$1.0K–$15.0K
Traded
Aug 27, 2020
View
Financials
Financials
Revenue (FY)
$10.3B
Net income (FY)
$157.0M
EPS diluted
$0.42
View
Buybacks
Authorized
$50.0M
View
Filings
SEC Filings
Latest
10-Q
Filed
Oct 29, 2026
This year
18

Bausch Health Companies Inc. says refinancing extended approximately $6,870 million of debt maturities from 2025 through 2028 to 2030 through 2032 while it continues evaluating separation of approximately 87%-owned Bausch + Lomb.

View
Proposed Sales
Value
$258.9K
Shares
36.8K
Filed
Aug 19, 2026
View
Earnings & Events
Webcasts
Last webcast
Oct 28, 2026
View
Investor Relations
Latest news
BAUSCH HEALTH ANNOUNCES THIRD QUA…
Published
Oct 28, 2026
View

Performance

5D 20D 120D MTD YTD
BHC +3.8% +31.9% +61.2% +4.4% +23.2%
SPY -5.5% -6.3% -5.6% -5.3% +5.0%
vs SPY +9.2% +38.2% +66.8% +9.7% +18.2%

Capital returns

Buyback program · as of Oct 28, 2026
Authorized
$50.00M
Spent (derived)
—
Remaining
—

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 885590 CUSIP 071734107 13F (30d) 236 filings 214 filers Visit website Investor relations